Antibiotic Utilization During COVID-19: Are We Over-Prescribing?

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2023 Feb 25

PMID 36830218

Authors

Natasa Bednarcuk

Ana Golic Jelic

Svjetlana Stoisavljevic Satara

Natasa Stojakovic

Vanda Markovic Pekovic

Milos P Stojiljkovic

Nina Popovic

Ranko Skrbic

Affiliations

Soon will be listed here.

Abstract

The aims of this study were to analyze the utilization of antibiotics before (2018, 2019) and during the COVID-19 pandemic (2020) and the practice of prescribing antibiotics in outpatient settings for COVID-19 patients during the 2020-2022 period. The Anatomical Therapeutic Chemical Classification/Defined Daily Dose methodology was used for the analysis of outpatient antibiotic utilization in the Republic of Srpska. The data was expressed in DDD/1000 inhabitants/day. The rate of antibiotics prescribed to COVID-19 outpatients was analyzed using medical record data from 16,565 patients registered with B34.2, U07.1, and U07.2 World Health Organization International Classification of Diseases 10th revision codes. During 2020, outpatient antibiotic utilization increased by 53.80% compared to 2019. At least one antibiotic was prescribed for 91.04%, 83.05%, and 73.52% of COVID-19 outpatients during 2020, 2021, and the first half of 2022, respectively. On a monthly basis, at least one antibiotic was prescribed for more than 55% of COVID-19 outpatients. The three most commonly prescribed antibiotics were azithromycin, amoxicillin/clavulanic acid, and doxycycline. The trend of repurposing antibiotics for COVID-19 and other diseases treatment might be a double-edged sword. The long-term effect of this practice might be an increase in antimicrobial resistance and a loss of antibiotic effectiveness.

Citing Articles

Early initiation of ceftaroline-based combination therapy for methicillin-resistant Staphylococcus aureus bacteremia.

Hicks A, Dolan M, Shah M, Elwood S, Platts-Mills J, Madden G Ann Clin Microbiol Antimicrob. 2025; 24(1):3.

PMID: 39806392 PMC: 11730128. DOI: 10.1186/s12941-025-00773-z.

Antimicrobial Prescribing Patterns in GP Practices in Northern Ireland.

Coleman H, Clifford E, Rajiah K, Ali N, Courtenay A, Lowry D Antibiotics (Basel). 2024; 13(11).

PMID: 39596743 PMC: 11591126. DOI: 10.3390/antibiotics13111050.

Impact of a package of point-of-care diagnostic tests, a clinical diagnostic algorithm and adherence training on antibiotic prescriptions for the management of non-severe acute febrile illness in primary health facilities during the COVID-19....

Kiemde F, Nkeramahame J, Ibarz A, Dittrich S, Olliaro P, Valia D BMC Infect Dis. 2024; 24(1):870.

PMID: 39192209 PMC: 11351252. DOI: 10.1186/s12879-024-09787-y.

The Impact of SARS-CoV-2 Pandemic on Antibiotic Prescriptions and Resistance in a University Hospital from Romania.

Zaha D, Ilea C, Dorobantu F, Pantis C, Pop O, Dascal D Antibiotics (Basel). 2024; 13(6).

PMID: 38927144 PMC: 11200525. DOI: 10.3390/antibiotics13060477.

Exploring factors shaping antibiotic resistance patterns in during the 2020 COVID-19 pandemic.

Kovacevic A, Smith D, Rahbe E, Novelli S, Henriot P, Varon E Elife. 2024; 13.

PMID: 38451256 PMC: 10923560. DOI: 10.7554/eLife.85701.

References

Pannucci C, Wilkins E . Identifying and avoiding bias in research. Plast Reconstr Surg. 2010; 126(2):619-625. PMC: 2917255. DOI: 10.1097/PRS.0b013e3181de24bc. View

Lepak A, Taylor L, Stone C, Schulz L, Anderson M, Fox B . Association of Changes in Seasonal Respiratory Virus Activity and Ambulatory Antibiotic Prescriptions With the COVID-19 Pandemic. JAMA Intern Med. 2021; 181(10):1399-1402. PMC: 8218231. DOI: 10.1001/jamainternmed.2021.2621. View

Yates P, Newman S, Oshry L, Glassman R, Leone A, Reichel E . Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease. Ther Adv Respir Dis. 2020; 14:1753466620951053. PMC: 7476338. DOI: 10.1177/1753466620951053. View

. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021; 397(10279):1063-1074. PMC: 7972318. DOI: 10.1016/S0140-6736(21)00461-X. View

Gendrot M, Andreani J, Jardot P, Hutter S, Delandre O, Boxberger M . In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2. Molecules. 2020; 25(21). PMC: 7663271. DOI: 10.3390/molecules25215064. View

Belleudi V, Finocchietti M, Fortinguerra F, Di Filippo A, Trotta F, Davoli M . Drug Prescriptions in the Outpatient Management of COVID-19: Evidence-Based Recommendations Versus Real Practice. Front Pharmacol. 2022; 13:825479. PMC: 8988061. DOI: 10.3389/fphar.2022.825479. View

Mandell L, Marrie T, Grossman R, Chow A, Hyland R . Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis. 2000; 31(2):383-421. DOI: 10.1086/313959. View

Markovic-Pekovic V, Grubisa N . Self-medication with antibiotics in the Republic of Srpska community pharmacies: pharmacy staff behavior. Pharmacoepidemiol Drug Saf. 2012; 21(10):1130-3. DOI: 10.1002/pds.3218. View

Llor C, Bjerrum L . Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther Adv Drug Saf. 2014; 5(6):229-41. PMC: 4232501. DOI: 10.1177/2042098614554919. View

10.

Gautret P, Lagier J, Parola P, Hoang V, Meddeb L, Mailhe M . RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56(1):105949. PMC: 7102549. DOI: 10.1016/j.ijantimicag.2020.105949. View

11.

Knight B, Shurgold J, Smith G, MacFadden D, Schwartz K, Daneman N . The impact of COVID-19 on community antibiotic use in Canada: an ecological study. Clin Microbiol Infect. 2021; 28(3):426-432. PMC: 8556063. DOI: 10.1016/j.cmi.2021.10.013. View

12.

Kitano T, Brown K, Daneman N, MacFadden D, Langford B, Leung V . The Impact of COVID-19 on Outpatient Antibiotic Prescriptions in Ontario, Canada; An Interrupted Time Series Analysis. Open Forum Infect Dis. 2021; 8(11):ofab533. PMC: 8601042. DOI: 10.1093/ofid/ofab533. View

13.

Bojanic L, Markovic-Pekovic V, Skrbic R, Stojakovic N, ermanovic M, Bojanic J . Recent Initiatives in the Republic of Srpska to Enhance Appropriate Use of Antibiotics in Ambulatory Care; Their Influence and Implications. Front Pharmacol. 2018; 9:442. PMC: 5987173. DOI: 10.3389/fphar.2018.00442. View

14.

Godman B, Wettermark B, van Woerkom M, Fraeyman J, Alvarez-Madrazo S, Berg C . Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol. 2014; 5:106. PMC: 4060455. DOI: 10.3389/fphar.2014.00106. View

15.

Hsu A, Barrett C, DeBusk G, Ellson C, Gautam S, Talmor D . Kinetics and Role of Plasma Matrix Metalloproteinase-9 Expression in Acute Lung Injury and the Acute Respiratory Distress Syndrome. Shock. 2015; 44(2):128-36. PMC: 4830084. DOI: 10.1097/SHK.0000000000000386. View

16.

Verheij R, Curcin V, Delaney B, McGilchrist M . Possible Sources of Bias in Primary Care Electronic Health Record Data Use and Reuse. J Med Internet Res. 2018; 20(5):e185. PMC: 5997930. DOI: 10.2196/jmir.9134. View

17.

Malek A, Granwehr B, Kontoyiannis D . Doxycycline as a potential partner of COVID-19 therapies. IDCases. 2020; 21:e00864. PMC: 7298522. DOI: 10.1016/j.idcr.2020.e00864. View

18.

Kim H, Luo L, Pflugfelder S, Li D . Doxycycline inhibits TGF-beta1-induced MMP-9 via Smad and MAPK pathways in human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2005; 46(3):840-8. DOI: 10.1167/iovs.04-0929. View

19.

Loganathan B, Phillips M, Mowery H, Jones-Lepp T . Contamination profiles and mass loadings of macrolide antibiotics and illicit drugs from a small urban wastewater treatment plant. Chemosphere. 2009; 75(1):70-7. DOI: 10.1016/j.chemosphere.2008.11.047. View

20.

Langford B, So M, Raybardhan S, Leung V, Soucy J, Westwood D . Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021; 27(4):520-531. PMC: 7785281. DOI: 10.1016/j.cmi.2020.12.018. View